Last updated: February 24, 2026
What is the drug associated with NDC 51407-0657?
NDC 51407-0657 corresponds to Humira Pen (Adalimumab), a monoclonal antibody used to treat autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, and psoriasis. It is marketed by AbbVie.
Current Market Landscape
Market Size and Demand
- The global autoimmune disease treatment market was valued at approximately $50 billion in 2022.[1]
- Humira accounted for over 20% of this market, with global sales reaching $21.2 billion in 2022.[2]
- Key indications include rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and plaque psoriasis.
Competitive Environment
- Primary competitors include Enbrel (etanercept), Remicade (infliximab), and Stelara (ustekinumab).
- Biosimilars entered the market in 2019-2020, challenging Humira’s dominance.
- In the U.S., multiple biosimilars have gained FDA approval, with some launched by Mylan, Amgen, and Sandoz.
Regulatory Status
- Humira is FDA-approved and patent-expired in some jurisdictions.
- Biosimilar approvals vary by region, with the U.S. biosimilar market evolving rapidly since 2019.[3]
- Patent litigation and patent thickets have delayed biosimilar market penetration in the U.S.
Price Trends and Projections
Current Pricing
- The list price for a single Humira injection is approximately $5,900.
- In the U.S., Medicaid and insurance negotiations reduce actual patient costs.
- Biosimilars are priced roughly 15-30% lower than the original biologic.[4]
Price Impact of Biosimilars
- US biosimilars launched between 2019 and 2022 decreased Humira's price by an estimated 20-25%.[5]
- Inflations and negotiated discounts further affect net pricing.
Future Price Projections
| Year |
Estimated Average Price (per injection) |
Notes |
| 2023 |
$4,200 - $4,800 |
Ongoing biosimilar market competition |
| 2025 |
$3,800 - $4,300 |
Increased biosimilar adoption in U.S. |
| 2030 |
$3,500 - $4,000 |
Likely further biosimilar penetration, possible patent expiry in other regions |
Pricing Drivers
- Biosimilar entry and market competition.
- Healthcare policy and payer negotiations.
- Manufacturing costs and supply chain efficiencies.
- Patent litigation outcomes and regulatory pathways.
Market Projections Summary
- The U.S. market for Humira and biosimilars is expected to decline in list prices through 2030 due to biosimilar competition.
- Overall autoimmune biologic revenues will grow at a CAGR of approximately 4-6% driven by increasing diagnosis rates, new indications, and innovations.[6]
- Industry trends indicate standardization of biosimilar pricing, potentially stabilizing net prices after initial discounts.
Key Impact Factors
- Patent litigation timing and outcomes.
- Regulatory pathway developments, including interchangeability approvals.
- Physician and patient uptake of biosimilars.
- Changes in healthcare policy affecting drug reimbursement.
Important Considerations
- The actual profit margins will vary based on negotiation strategies with payers.
- Localized pricing policies differ; global market prices will follow regional regulatory trends.
- Future pricing strategies may include dose optimization and alternative administration methods to sustain revenues.
Key Takeaways
- Humira (NDC 51407-0657) remains a dominant biologic with significant revenue impact, though biosimilar entry diminishes list prices.
- The U.S. biosimilar market significantly affects price projections, with prices expected to decrease by up to 30% by 2025.
- Industry trends point toward stabilized net prices through negotiated discounts and increased biosimilar adoption.
- Future market growth depends on regulatory and patent landscapes, as well as clinical acceptance of biosimilars.
FAQs
1. How will biosimilar competition impact Humira prices through 2030?
Biosimilar competition is expected to reduce list prices by approximately 15-30% over the next few years, with further discounts possibly emerging as market penetration increases.
2. What regions are most affected by biosimilar entry?
The U.S. experiences the most significant price reductions due to biosimilar entry, followed by Europe, where biosimilars gained earlier approval.
3. Can manufacturing costs influence future pricing?
Yes. Advances in manufacturing efficiency and supply chain optimization can lower production costs, potentially impacting prices.
4. Are there any regulatory developments that could alter price projections?
Yes. Regulatory pathways for interchangeability and accelerated approval can influence biosimilar market share and, consequently, price dynamics.
5. What indications are driving the demand for Humira?
Rheumatoid arthritis, Crohn’s disease, and psoriasis are primary drivers, with increasing diagnosis rates and expanded indications contributing to steady demand.
References
- MarketWatch. (2022). Autoimmune Disease Treatment Market Size, Share & Trends.
- AbbVie Annual Report. (2022). Humira Sales Data.
- FDA. (2022). Biosimilar Approval Summary.
- IQVIA. (2022). US Biosimilar Market Report.
- Scrip. (2022). Biosimilar Pricing Trends.
- EvaluatePharma. (2022). Biologics Market Forecast.
Note: Data reflects latest available estimates as of 2023 and may vary with future regulatory, market, and competitive developments.
